{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T11:43:24Z","timestamp":1792669404606,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jtct.2026.09.048","type":"journal-article","created":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T15:27:27Z","timestamp":1791041247000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["CAR T\u2011Cell Therapy as a Bridging Strategy to Second Transplant in Relapsed B\u2011Cell ALL"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6383-3777","authenticated-orcid":false,"given":"Vaibhav","family":"Agrawal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoyue","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monzr Al","family":"Malki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amandeep","family":"Salhotra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Aribi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Koller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karamjeet","family":"Sandhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salman","family":"Otoukesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haris","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoda","family":"Pourhassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0803-9607","authenticated-orcid":false,"given":"Andrew","family":"Artz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamer","family":"Othman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yazeed","family":"Samara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Len","family":"Farol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1786-1398","authenticated-orcid":false,"given":"Anthony","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryotaro","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Marcucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod","family":"Pullarkat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Forman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Aldoss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2026.09.048_bib0001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/OTT.S274551","article-title":"Post-hematopoietic cell transplantation relapsed acute lymphoblastic leukemia: current challenges and future directions","volume":"16","author":"Varadarajan","year":"2023","journal-title":"Onco Targets Ther"},{"issue":"4","key":"10.1016\/j.jtct.2026.09.048_bib0002","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/s41409-020-01101-z","article-title":"Prognostic factors for survival after allogeneic transplantation in acute lymphoblastic leukemia","volume":"56","author":"Greil","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1016\/j.jtct.2026.09.048_bib0003","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/bmt.2012.195","article-title":"Outcomes of second allogeneic hematopoietic stem cell transplantation for patients with acute lymphoblastic leukemia","volume":"48","author":"Poon","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"19","key":"10.1016\/j.jtct.2026.09.048_bib0004","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1182\/blood.2023023568","article-title":"Management of ALL in adults: 2024 ELN recommendations from a European expert panel","volume":"143","author":"Gokbuget","year":"2024","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.jtct.2026.09.048_bib0005","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1038\/bmt.2015.186","article-title":"Second allogeneic transplantation for relapse of malignant disease: retrospective analysis of outcome and predictive factors by the EBMT","volume":"50","author":"Ruutu","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"10.1016\/j.jtct.2026.09.048_bib0006","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/sj.bmt.1704645","article-title":"Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant","volume":"34","author":"Eapen","year":"2004","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.jtct.2026.09.048_bib0007","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.bbmt.2018.09.016","article-title":"Outcomes after second hematopoietic cell transplantation in children and young adults with relapsed acute leukemia","volume":"25","author":"Lund","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"10.1016\/j.jtct.2026.09.048_bib0008","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.bbmt.2013.04.014","article-title":"Outcomes of adults with acute lymphoblastic leukemia relapsing after allogeneic hematopoietic stem cell transplantation","volume":"19","author":"Poon","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"10.1016\/j.jtct.2026.09.048_bib0009","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.jtct.2026.09.048_bib0010","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.jtct.2026.09.048_bib0011","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1002\/cncr.33340","article-title":"Sequencing of novel agents in relapsed\/refractory B-cell acute lymphoblastic leukemia: blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed\/refractory acute lymphoblastic leukemia","volume":"127","author":"Badar","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.jtct.2026.09.048_bib0012","first-page":"71","article-title":"Improving access to bone marrow transplant and cellular therapies","volume":"13","author":"Blackmon","year":"2024","journal-title":"Targeted Therap Oncol"},{"issue":"446","key":"10.1016\/j.jtct.2026.09.048_bib0013","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"issue":"535","key":"10.1016\/j.jtct.2026.09.048_bib0014","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1080\/01621459.2020.1713792","article-title":"Regression models and multivariate life tables","volume":"116","author":"Prentice","year":"2021","journal-title":"J Am Stat Assoc"},{"issue":"4","key":"10.1016\/j.jtct.2026.09.048_bib0015","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1158\/1078-0432.CCR-22-2038","article-title":"Favorable activity and safety profile of memory-enriched CD19-targeted chimeric antigen receptor T-cell therapy in adults with high-risk relapsed\/refractory ALL","volume":"29","author":"Aldoss","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"14","key":"10.1016\/j.jtct.2026.09.048_bib0016","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1182\/blood.2023022922","article-title":"The present and future of CAR T-cell therapy for adult B-cell ALL","volume":"145","author":"Rampotas","year":"2025","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.jtct.2026.09.048_bib0017","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2025-443","article-title":"CD19-CAR T cell therapy as a definitive consolidation in older adults with b-ALL in CR1 is safe and induces durable MRD- remission","volume":"146","author":"Aldoss","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.09.048_bib0018","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40164-018-0125-6","article-title":"Outcomes following second allogeneic stem cell transplant for disease relapse after T cell depleted transplant correlate with remission status and remission duration after the first transplant","volume":"8","author":"Fan","year":"2019","journal-title":"Exp Hematol Oncol"},{"issue":"8","key":"10.1016\/j.jtct.2026.09.048_bib0019","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1038\/s41375-024-02318-3","article-title":"How risky is a second allogeneic stem cell transplantation?","volume":"38","author":"Penack","year":"2024","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.jtct.2026.09.048_bib0020","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.bbmt.2019.04.010","article-title":"Blinatumomab for acute lymphoblastic leukemia relapse after allogeneic hematopoietic stem cell transplantation","volume":"25","author":"Stein","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jtct.2026.09.048_bib0021","doi-asserted-by":"crossref","DOI":"10.1080\/16078454.2024.2422151","article-title":"Efficacy and safety of blinatumomab for the treatment of patients relapsing after allogeneic hematopoietic cell transplantation: a systemic review and meta-analysis","volume":"29","author":"Guo","year":"2024","journal-title":"Hematology"},{"issue":"5","key":"10.1016\/j.jtct.2026.09.048_bib0022","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.3324\/haematol.2023.284310","article-title":"Impact of inotuzumab ozogamicin on outcome in relapsed or refractory acute B-cell lymphoblastic leukemia patients prior to allogeneic hematopoietic stem cell transplantation and risk of sinusoidal obstruction syndrome\/venous occlusive disease","volume":"109","author":"Kayser","year":"2024","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.jtct.2026.09.048_bib0023","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1038\/s41409-025-02639-6","article-title":"Outcome of second allogeneic hematopoietic cell transplantation in adult patients with relapsed B-cell acute lymphoblastic leukemia in the era of new immunotherapeutic agents","volume":"60","author":"Kwag","year":"2025","journal-title":"Bone Marrow Transplant"},{"issue":"16_suppl","key":"10.1016\/j.jtct.2026.09.048_bib0024","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.7001","article-title":"Outcomes following brexucabtagene autoleucel administered as an FDA-approved therapy for adults with relapsed\/refractory B-ALL","volume":"41","author":"Roloff","year":"2023","journal-title":"Journal of Clinical Oncology"},{"issue":"20","key":"10.1016\/j.jtct.2026.09.048_bib0025","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1182\/bloodadvances.2019000593","article-title":"Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy","volume":"3","author":"Shadman","year":"2019","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"10.1016\/j.jtct.2026.09.048_bib0026","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2025-6077","article-title":"Pre-transplant CAR T-cell therapy is associated with inferior survival and increased non-relapse mortality in pediatric B-ALL: a single-center retrospective analysis","volume":"146","author":"Chok","year":"2025","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.jtct.2026.09.048_bib0027","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1182\/bloodadvances.2022008981","article-title":"CD19 CAR T cells are an effective therapy for posttransplant relapse in patients with B-lineage ALL: real-world data from Germany","volume":"7","author":"Bader","year":"2023","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.jtct.2026.09.048_bib0028","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/ejh.14132","article-title":"Determinants of outcomes and advances in CD19-directed chimeric antigen receptor therapy for B-cell acute lymphoblastic leukemia","volume":"112","author":"Gupta","year":"2024","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jtct.2026.09.048_bib0029","article-title":"Recipient-derived vs. donor-derived CAR-T-cell therapy in relapsed B-cell acute lymphoblastic leukemia patients after transplantation: a multi-center retropective study","author":"Liu","year":"2025","journal-title":"Chin Med J (Engl)"},{"issue":"11","key":"10.1016\/j.jtct.2026.09.048_bib0030","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/j.jcyt.2024.05.021","article-title":"Efficacy and risk of donor-derived CAR-T treatment of relapsed B-cell acute lymphoblastic leukemia after hematopoietic stem cell transplantation","volume":"26","author":"Deng","year":"2024","journal-title":"Cytotherapy"},{"issue":"5","key":"10.1016\/j.jtct.2026.09.048_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcyt.2026.102074","article-title":"Long-term follow-up of CD19 chimeric antigen receptor T cell therapy in acute lymphoblastic leukemia patients relapsed after allogeneic hematopoietic stem cell transplantation","volume":"28","author":"Fu","year":"2026","journal-title":"Cytotherapy"},{"issue":"4","key":"10.1016\/j.jtct.2026.09.048_bib0032","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jcyt.2024.11.016","article-title":"Post-transplant relapse in pediatric acute lymphoblastic leukemia in the era of CAR-T cell therapy. A multicenter analysis of Grupo Espanol de Trasplante Hematopoyetico y Terapia Celular (GETH-TC) Pediatric Committee","volume":"27","author":"Gonzalez Vicent","year":"2025","journal-title":"Cytotherapy"},{"issue":"11","key":"10.1016\/j.jtct.2026.09.048_bib0033","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1182\/bloodadvances.2024014846","article-title":"Real-world outcomes for young adult patients receiving CD19 CAR T-cell therapy","volume":"9","author":"Lust","year":"2025","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.jtct.2026.09.048_bib0034","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1038\/s41375-025-02532-7","article-title":"Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3","volume":"39","author":"Shah","year":"2025","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.jtct.2026.09.048_bib0035","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1200\/JCO.22.01076","article-title":"Outcomes after nonresponse and relapse post-tisagenlecleucel in children, adolescents, and young adults with B-cell acute lymphoblastic leukemia","volume":"41","author":"Schultz","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2026.09.048_bib0036","article-title":"Analysis benefits of a second Allo-HSCT after CAR-T cell therapy in patients with relapsed\/refractory B-cell acute lymphoblastic leukemia who relapsed after transplant","volume":"14","author":"Cao","year":"2023","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.jtct.2026.09.048_bib0037","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1182\/blood-2016-07-726588","article-title":"Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults","volume":"129","author":"Jain","year":"2017","journal-title":"Blood"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726007785?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726007785?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T11:11:14Z","timestamp":1792667474000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636726007785"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":37,"alternative-id":["S2666636726007785"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.09.048","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CAR T\u2011Cell Therapy as a Bridging Strategy to Second Transplant in Relapsed B\u2011Cell ALL","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.09.048","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}